Investors

Press Releases

All Releases

View Summary Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
May 31, 2016
PDF 14.8 KB Add to Briefcase
View Summary Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
May 26, 2016
PDF 17.6 KB Add to Briefcase
  Words of Support from Public Figures on Regeneron STS Sponsorship
May 26, 2016
PDF 122.8 KB Add to Briefcase
  Regeneron Announces Important US Prescribing Information Clarification for EYLEA® (aflibercept) Injection
May 25, 2016
PDF 116.7 KB Add to Briefcase
  Regeneron and Sanofi Genzyme to Present Additional Data from Pivotal Phase 2b Dupilumab Study in Adults with Uncontrolled Persistent Asthma at the American Thoracic Society International Conference
May 11, 2016
PDF 127.1 KB Add to Briefcase
View Summary Regeneron Reports First Quarter 2016 Financial and Operating Results
May 5, 2016
PDF 46.8 KB Add to Briefcase
View Summary Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
May 2, 2016
PDF 15.6 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2016 Investor Conference Presentations
Apr 29, 2016
PDF 10.3 KB Add to Briefcase
View Summary Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Apr 15, 2016
PDF 8.5 KB Add to Briefcase
  Regeneron Hires Sally A. Paull as Senior Vice President, Human Resources
Apr 13, 2016
PDF 72.9 KB Add to Briefcase
View Summary Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Apr 11, 2016
PDF 13.9 KB Add to Briefcase
  Regeneron and MedImmune Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer
Apr 5, 2016
PDF 269.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Apr 1, 2016
PDF 22.9 KB Add to Briefcase
  Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Trial Data at ACC.16
Mar 30, 2016
PDF 196.9 KB Add to Briefcase
View Summary Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Mar 24, 2016
PDF 14.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Mar 23, 2016
PDF 21.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Mar 16, 2016
PDF 20.5 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Mar 11, 2016
PDF 20.1 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Humana Provides Exclusive or Preferred Access to Praluent® (alirocumab) Injection on their Commercial and Medicare Formularies
Mar 4, 2016
PDF 17.2 KB Add to Briefcase
View Summary Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Mar 2, 2016
PDF 15.9 KB Add to Briefcase
Showing 1-20 of 334 Page: 1 2 3 4 5 ... 17  Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)